Ruud H. Wijdeven

The Netherlands Cancer Institute

Papers

1

Total Citations

32

H-Index

1

About

Ruud H. Wijdeven is a molecular biologist whose research centers on DNA damage repair, cancer biology, and the development of targeted therapies. His most notable contribution is the identification of a novel ATM inhibitor that exhibits cancer cell-specific radiosensitization activity, a breakthrough detailed in his 2017 paper. This work demonstrated that the inhibitor selectively enhances the sensitivity of cancer cells to radiation therapy while sparing normal cells, a critical advancement in improving treatment outcomes for patients with head and neck cancers and other malignancies. With 32 citations, this study has garnered attention for its translational potential in oncology. Wijdeven’s research integrates mechanistic insights into DNA repair pathways with preclinical drug development, aiming to overcome radioresistance in tumors. His collaborative approach, involving experts in chemical biology and radiotherapy, underscores his ability to bridge fundamental science and clinical application. For students and researchers, Wijdeven’s work exemplifies how targeting specific molecular vulnerabilities can lead to more effective and less toxic cancer treatments, highlighting the promise of precision medicine in radiation oncology.

Research Focus

Key Achievements

1
H-Index
1
Papers
32
Total Citations
32
Avg Citations/Paper
🏆 Most Cited Paper
Identification of a novel ATM inhibitor with cancer cell specific radiosensitization activity
32 citations · 2017
📈 Most Prolific Year: 2017 (1 Papers)
🤝 Key Collaborators: 12
🏛 Institutions: The Netherlands Cancer Institute

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 11 days ago